Loading...
Docoh

InMed Pharmaceuticals (INM)

News

From Benzinga Pro
InMed Pharmaceuticals Is Commercializing The Development Of Rare Cannabinoids For The Wellness Market
17 May 22
Cannabis, Markets
Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc. (Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug development.
InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition
13 May 22
Cannabis, Earnings, News, Penny Stocks, Markets
InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022.
InMed Pharmaceuticals Q3 EPS $(0.25) Up From $(0.41) YoY, Sales $309.59K
13 May 22
Earnings, News
InMed Pharmaceuticals (NASDAQ:INM) reported quarterly losses of $(0.25) per share. This is a 39.02 percent increase over losses of $(0.41) per share from the same period last year. The company reported $309.59 thousand
20 Stocks Moving in Tuesday's Pre-Market Session
3 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and MicroSafe Group DMCC reported EPA approval for Nanocyn hospital-grade disinfectant in the U.S.
66 Biggest Movers From Yesterday
3 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday.
InMed Expands Patent Portfolio With Novel Cannabinoid Analogs And Advances Collaboration Agreement With Leading Cannabinoid Research Expert
28 Apr 22
News, FDA, Legal
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the
18 Stocks Moving in Tuesday's Pre-Market Session
26 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday.
InMEd Pharma Highlights Launch Of Business-To-Business Sales Of Rare Cannabinoid Cannabidivarin To Wholesalers, Suppliers, End-Product Manufacturers
21 Apr 22
Biotech, Cannabis, News, FDA, Markets, General
Expands rare cannabinoid portfolio beyond current CBC and CBT Releases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21,
63 Biggest Movers From Yesterday
25 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire.
Stocks That Hit 52-Week Lows On Wednesday
2 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 107 companies set new 52-week lows.

Press releases

From Benzinga Pro
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
13 May 22
Earnings, Press Releases
Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel cannabinoid analogsAdvances the pharmaceutical drug development programs in EB,
InMed to Supply Rare Cannabinoids to Radicle Science's "Radicle Energy Study" to Assess the Health Effects of THCV
5 May 22
Health Care, Press Releases
Study will use delta-9 dominant THCV manufactured by InMed's subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on cannabinoids for
InMed Pharmaceuticals (INM): Notable Launches of High-Value Rare Cannabinoids
3 May 22
News, Press Releases
LONDON, UK / ACCESSWIRE / May 3, 2022 / InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
28 Apr 22
News, Legal, Press Releases
Expands library of proprietary cannabinoid analogs for pharma R&DResearch collaboration initiated to screen analogs for therapeutic uses VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 28, 2022
InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
21 Apr 22
Press Releases, General
Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., April 21, 2022
InMed to Participate in Upcoming Investor Conferences in April and May 2022
19 Apr 22
News, Health Care, Press Releases
VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare
InMed Announces Management Changes
17 Mar 22
News, Management, Press Releases
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare
InMed to Present at the 34th Annual Roth Conference
8 Mar 22
News, Health Care, Press Releases
Vancouver, BC, March 08, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of